Movement Alert|Elevance Health Rises 3.09% in Regular Trading, Multiple Investment Banks Raise Target Prices Boosting Sentiment

Market Focus
06/04

On June 4, Elevance Health rose 3.09% in regular trading, trading at $406.27/share, with trading volume of $93.83 million.

On the news front, Morgan Stanley raised its target price on Elevance Health from $352 to $404, maintaining an equal-weight rating. Earlier, Truist also significantly raised its target price from $375 to $450, maintaining a buy rating. According to FactSet, the stock now carries an average analyst rating of overweight with a mean target price of approximately $406.

The broader Managed Health Care sector rallied in tandem, providing additional tailwinds. Among sector peers, Alignment Healthcare rose 8.14%, Humana rose 6.2%, UnitedHealth rose 5.97%, Centene rose 5.82%, and Molina Healthcare rose 4.37%, reflecting broad-based industry strength.

Elevance Health is a leading U.S. health benefits company operating under the Anthem Blue Cross and Blue Shield, Wellpoint, and Carelon brands, serving approximately 45.2 million medical members across multiple states.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10